Navigation Links
A calculator to estimate the likelihood of antidepressant response
Date:7/1/2013

Philadelphia, PA-- As in any other field of medicine, when a depressed person visits a psychiatrist for treatment of depression, they like to be informed of the odds that they will respond to the medication they are prescribed. Unfortunately, there has been no precise way to predict antidepressant response in individual patients.

It would be very nice to have an equation that would enable doctors to predict the likelihood that individual patients would respond to specific treatments. Accurate predictions are likely to be challenging. The ability to accurately predict the likelihood of antidepressant response for individual patients could be an important step in developing individualized treatment plans.

The effectiveness of antidepressant medications varies tremendously across patients and the overall effectiveness of current medications is lower than previously expected. For example, the largest antidepressant trial ever conducted -- the NIMH STAR*D study -- provided somewhat discouraging news about the effectiveness of antidepressants. Only 30% of patients responded to their initial antidepressant and after one year and up to four different treatments, 30% of patients did not achieve remission.

In this issue of Biological Psychiatry, Dr. Roy Perlis at Massachusetts General Hospital has taken an important step toward this objective.

He gathered data collected from the STAR*D study and used multiple prediction models to identify statistical patterns. Using the best-performing model, he then generated an online risk calculator and visualization tool that provides a graphical estimate of an individuals' risk for treatment resistance.

"To address the needs of individual depressed patients, we will need to find ways to design psychiatric treatments to respond to the differences among patients with depression. The 'depression calculator' that emerges from the STAR*D trial is one step forward in this effort," said Dr. John Krystal, Editor of Biological Psychiatry. "To do better than this, we will need to include biomarkers that may serve the function that blood tests and blood pressure measurements serve in other areas of medicine."

Perlis agrees, commenting that "There has been great emphasis on the discovery of biomarkers to help predict clinical outcomes. No doubt this effort will succeed eventually. On the other hand, it's entirely possible that clinical features can help get us part of the way there - that clinical features can help make useful predictions."

"The analogy I would draw is the Framingham score for predicting cardiovascular risk. It's far from perfect, and there's plenty to criticize - but it has at least spurred efforts to use prediction in a clinical setting. It has also provided a platform to which biomarkers can be added, as they are identified," he added.

In the meantime, the whole point of providing a clinical calculator online is to allow clinicians to try it out - to see what could be done, if the will and the resources were there.


'/>"/>

Contact: Rhiannon Bugno
Biol.Psych@utsouthwestern.edu
214-648-0880
Elsevier
Source:Eurekalert

Related biology news :

1. Measuring mercury: Common test may overestimate exposure from dental amalgam fillings
2. New online tool estimates carbon and energy impact of trees
3. US underestimates costs of carbon pollution and climate change
4. Atmospheric scientists release first bottom-up estimates of Chinas CO2 emissions
5. Developing world has less than 5 percent chance of meeting UN child hunger target, study estimates
6. Ability to estimate quantity increases in first 30 years of life
7. Environmental benefit of biofuels is overestimated, new study reveals
8. Scientists provide first large-scale estimate of reef shark losses in the Pacific Ocean
9. Wind pushes plastics deeper into oceans, driving trash estimates up
10. New research lowers past estimates of sea-level rise
11. Costs for changing pollution criteria in Florida waters likely to exceed EPA estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... The global wearable medical device market, in terms of ... USD 5.31 billion in 2016, at a CAGR of 18.0% during ... ... in medical devices, launch of a growing number of smartphone-based healthcare ... healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... Research Future has a half cooked research report on Global Liquid ... and expected to reach USD 450 Million by the end of ... ... assessed as a swiftly growing market and expected that the market ... There has been a tremendous growth in the prevalence of cancer ...
(Date:1/19/2017)... and Markets ... addition of the "Implantable Biomaterials Market Analysis & ... to their offering. Report Highlights: ... current and future market trends to identify the investment opportunities ... numbers Key market trends across the business segments, Regions ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
Breaking Biology Technology: